Dermata TherapeuticsDRMA
13F holders, Q3 2024 (September 30)4holders −2
0new positions
2sold out
$1.64avg. 13F price*
At the end of Q3 2024, 4 institutions reported holding Dermata Therapeutics Inc. (DRMA) in their 13F filings, down 2 from Q2 2024. 0 opened new positions and 2 sold out. The largest holders were Tower Research Capital LLC (TRC) ($5K), Wells Fargo & Company ($3K) and UBS Group AG ($2K).
- Company
- Dermata Therapeutics Inc.
- CUSIP
- 249845405
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $70K |
All 13F filers, Q2 2024 → Q3 2024: 3,165 shares bought and 29,491 shares sold, net −26,326 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Tower Research Capital LLC (TRC) | 0.00% | Add +66.8% | 2,892 | $5K |
| Wells Fargo & Company | 0.00% | Add +4444.4% | 2,045 | $3K |
| UBS Group AG | 0.00% | Reduce -12.2% | 1,497 | $2K |
| Bank of America Corp. | 0.00% | Add +233.3% | 10 | $16 |
"% of holder's portfolio" is DRMA's weight in each manager's 13F, not the share of Dermata Therapeutics Inc. the manager owns.